Nuclear cloning of embryonal carcinoma cells.
Level 5 - mechanism / opinion, no new human data
Bench research using mouse cell lines and animal nuclear transplantation without human clinical data.
PubMed 15306687 · doi:10.1073/pnas.0405015101
What was done
Researchers performed nuclear transplantation using nuclei from three independent mouse embryonal carcinoma (EC) cell lines (F9, P19, and METT-1) into enucleated oocytes to determine whether tumorigenic and developmental limits are driven by epigenetic or genetic alterations. Derived blastocysts were cultured to generate nuclear transfer embryonic stem (NT ES) cell lines, which were evaluated for tumor and chimera formation alongside comparative genomic hybridization.
What was found
Nuclei from all three EC lines successfully directed early development into morphologically normal blastocysts and yielded NT ES cell lines at high efficiency, though specific numerical rates were not stated in the abstract. The resulting NT ES cells retained the identical developmental and tumorigenic potential of their donor EC cells, and comparative genomic hybridization identified uncharacterized genetic lesions in the donor lines.
Why it matters
These findings show that nonreprogrammable genetic mutations, rather than reversible epigenetic modifications alone, govern the tumorigenic and developmental restrictions of embryonal carcinoma cells.
Limits
The abstract provides no quantitative data, sample sizes for reconstructed embryos, or statistical analyses. The study is limited to three mouse cell lines in a preclinical model, precluding direct clinical generalization.
Cited by
- contradicts Nuclear transfer experiments show that placing a cancer cell nucleus into a normal enucleated cytoplasm results in normal cell differentiation and suppresses tumor formation, contradicting the somatic mutation theory of cancer.